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Health Sciences, Universiti Malaysia, Sarawak, MalaysiaA B S T R A C TObjectives: This study’s objectives were to estimate the quality of life
(QOL) of Malaysian patients with acute coronary syndrome (ACS)
during admission and at 12 months, to explore the factors associated
with the QOL, and to compare utility scores derived from tariffs from
local and foreign populations. Methods: Data collected from patients
with ACS between 2008 and 2009 for a study on cardiac rehabilitation
at the Sarawak General Hospital were used for this study. QOL data
were obtained using a validated version of the EuroQol ﬁve-
dimensional questionnaire at baseline and at 12 months. Health
utility scores were calculated using visual analogue scale scores and
utility tariffs from Malaysia and the United Kingdom. Results: Data
from 104 subjects from the earlier study was used. The mean age was
56.1 years, with 88.5% being men. The mean hospitalization duration
was 6.3 days. The mean utility score was 0.75 at baseline and 0.82 at
12 months. There was a statistically signiﬁcant improvement in utilityee front matter Copyright & 2015, International S
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.1016/j.vhri.2015.03.015
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Selangor, Malaysia.from baseline to 12 months based on the Malaysian tariff (P ¼ 0.014)
but not with the UK tariff (P ¼ 0.086). The QOL of patients was
associated with sex and diagnosis of ST-segment elevation myocar-
dial infarction. Conclusions: Our results showed that there was a
signiﬁcant improvement in the QOL from baseline to 12 months. Only
sex and diagnosis affected the QOL score at baseline because of
limited variables available for testing. It also reconﬁrms the impor-
tance of applying the appropriate, country-speciﬁc utility tariffs in
QOL studies. Despite limitations, the study is useful toward describing
QOL among a group of Malaysian patients with ACS.
Keywords: acute coronary syndrome, EQ-5D, Malaysia, quality of life,
utility.
Copyright & 2015, International Society for Pharmacoeconomics and
Outcomes Research (ISPOR). Published by Elsevier Inc.Introduction
Acute coronary syndrome (ACS) is one of the leading causes of
morbidity and mortality globally, as well as in Malaysia [1–4]. In
2012, it accounted for 24.7% of all recorded deaths in the country
[3]. Diseases of the circulatory system also represent a signiﬁcant
burden to the nation’s health system, with 7.4% of hospital-
izations [3]. These rates are poised to rise as disease patterns in
this middle-income developing country become more similar to
those of developed countries [5].
Commonly known as a “heart attack,” ACS occurs when there
is obstruction of the coronary arteries resulting in restricted blood
ﬂow to the heart [6]. It can be classiﬁed into three intensity
categories: unstable angina (UA); non–ST-segment elevation
myocardial infarction (NSTEMI), in which coronary arteries are
partially or intermittently occluded; and ST-segment elevation
myocardial infarction (STEMI), in which there is full arterial
occlusion [6–9].As can be expected, patients with or recovering from ACS
have poorer quality of life (QOL) [10,11]. Management strategies
that help patients gain clinical and QOL improvements are
preferable over others; therefore, understanding the factors that
affect the QOL is helpful [12]. QOL outcomes may also be
prognostic in predicting subsequent morbidity and mortality in
patients with coronary disease [13]. Studies that have reported
QOL among patients with ACS are mostly from developed
countries. Among the demographic and clinical factors that have
been identiﬁed to have an impact were age [14,15], sex [14–18], a
previous cardiovascular (CV) event [16,19], angina severity [16],
type of ACS [18,20], depression [16,17,21], and physical function-
ing [15,18,19]. From Malaysia, a study by Chin et al. [4] reported
that patients’ age, percutaneous coronary intervention (PCI), and
ﬁbrinolytic therapy were factors associated with patient mortality
but did not report QOL-related factors.
The EuroQol ﬁve-dimensional questionnaire is a ﬁve-question
descriptive system QOL instrument that also allows calculation ofociety for Pharmacoeconomics and Outcomes Research (ISPOR).
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Several utility tariffs have been developed on the basis of stated
health preferences of respondents from different countries
including the United Kingdom [26], Japan [27], Korea [25], New
Zealand [28], the United States [29], and Malaysia [30]. When local
tariffs are not available, studies have applied utility tariffs from
other countries, such as the UK population tariff or others [26].
There is, however, evidence to suggest that when available, local
tariffs should be used to calculate the quality-adjusted life-years
of any given country’s population [25,30]. This is due to differ-
ences in health preferences and valuations that exist between
populations. In turn, these are possibly due to differences in
cultural values or perception of health and illness [30,31].
To our knowledge, there have been no published studies on
the QOL of patients with ACS from Malaysia or South East Asian
countries. This study sought to address this gap to better under-
stand the QOL impact of ACS in Malaysian patients. We esti-
mated the QOL of Malaysian patients with ACS at admission and
at 12 months after the ACS event and explored factors that are
associated with QOL. We also examined the statistical effects of
calculating the health utility of patients with ACS using utility
tariffs derived from the local (Malaysian) population compared
with the UK population tariff.Table 1 – Sample baseline characteristics.
Patient characteristic N Results
Age (y), mean  SD 103 56.1  10.4
Sex (%) 104
Male 92 88.5
Female 12 11.5
ACS diagnosis (%) 104
NSTEMI/UA 45 43.3
STEMI 58 55.8
Missing 1 0.9
Duration of hospitalization (d), mean  SD 104 6.3  8.4
CV risk factors (%) 104
o5 38 36.5
Z5 66 63.5
LVEF (%) 104
r50% 55 52.9
450% 49 47.1
Hypertension (%) 64 61.5
Diabetes mellitus (%) 31 29.8
Mean VAS score at baseline 104 0.60
Mean utility score at baseline 104 0.75Methods
Design and Setting
We used secondary data from an earlier economic evaluation of the
cardiac rehabilitation program at the Sarawak General Hospital,
Malaysia [32]. The study included patients with ACS who were
admitted to the hospital’s intensive cardiac care unit or cardiothora-
cic ward with an ACS diagnosis of STEMI, NSTEMI, or UA from
January 2008 to December 2009. Patients were younger than 75 years
and were required to be able to converse in English or the Malay
language to be eligible. Baseline and QOL data were collected on
admission, and follow-up data were collected at 12-month post-
hospitalization. Additional clinical data were also obtained through
review of medical records. The study was approved by the Malay-
sian Medical Research and Ethics Committee (NMRR-08-246-1401).
Statistical Analysis
Health utility scores were calculated by applying EuroQol ﬁve-
dimensional questionnaire utility tariffs from Malaysia [30] and
the United Kingdom [26] to the QOL reported by patients with
ACS in the study, as well as from visual analogue scale scores
completed by patients. EQ visual analogue scale scores were
rescaled to 0 to 1 for ease of analysis.
Factors associated with the QOL at baseline and at 12 months
were assessed using the Malaysian tariff only, and the analysis
was conducted using independent t tests with equality of var-
iances examined before conducting the t tests. Factors tested
included age, sex, type of ACS diagnosis, number of risk factors at
baseline (o5 or Z5), and left ventricular ejection fraction (r50%,
or4 50%). Separately, differences in utility scores at baseline and
at 12 months derived from the Malaysian and UK tariffs were
evaluated using paired t tests. The statistical signiﬁcance of
differences in utility scores between groups was ﬁxed at α o
0.05. All analyses were performed using STATA SE version 11.2
statistical software (StataCorp, College Station, TX).ACS, acute coronary syndrome; CV, cardiovascular; LVEF, left
ventricular ejection fraction; NSTEMI, non–ST-segment elevation
myocardial infarction; STEMI, ST-segment elevation myocardial
infarction; UA, unstable angina; VAS, visual analogue scale.Results
There were 112 subjects enrolled in the cardiac rehabilitation
program study of which 104 and 53 subjects provided QOLinformation at baseline and 12 months, respectively. The mean
age of the subjects was 56.1 years and 88.5% were men, while the
mean duration of hospitalization was 6.3 days (Table 1). Fifty-
eight (55.8%) patients were admitted with the diagnosis of STEMI.
Hypertension was present among 64 patients (61.5%), whereas 31
patients (29.8%) were diabetic at admission.
The QOL generally improved from baseline to 12 months after
the ACS event as reﬂected by the change in mean utility scores
(Table 2). Utility scores increased from 0.75 to 0.82 when calcu-
lated using the Malaysian utility tariff and were statistically
signiﬁcant (P ¼ 0.014). Utility scores calculated by the UK tariff
also improved from 0.63 to 0.72 but were not statistically
signiﬁcant (P ¼ 0.086). EQ visual analogue scale scores improved
from 0.60 at baseline to 0.71 and were highly signiﬁcant (P o
0.001).
Table 2 also presents demographic and clinical factors that are
associated with the QOL at baseline and at 12 months. Baseline
mean utility scores were associated with sex and ACS diagnosis.
Male patients had higher utility scores than did female patients
at 0.76 and 0.65, respectively (P ¼ 0.036). Similarly, patients with
STEMI diagnosis had better utility scores than did patients
diagnosed with NSTEMI/UA at 0.78 and 0.71, respectively (P ¼
0.045). No signiﬁcant differences in utility scores were observed
because of age, or the number of risk factors at baseline. Out of
104 patients who were included in the study at baseline, 53
patients (51.0%) were available to provide follow-up QOL data at
12 months post-ACS. At 12 months, there were no signiﬁcant
associations between clinical and demographic variables and
the QOL.Discussion
Similar to most studies from other countries, we found that the
QOL among Malaysian patients with myocardial infarction
improved from admission (baseline) to follow-up at 12 months.
A study of patients with myocardial infarction from Australia
Table 2 – Quality of life at baseline and at 12 mo with factors affecting the QOL.
Characteristic Baseline 12 mo
N (%) Utility score P-value N (%) Utility score P-value
Utility scores derived from the EQ-VAS
All patients 104 (100) 0.60 53 (100) 0.71 0.001
Utility scores calculated by UK utility tariff
All patients 104 (100) 0.63 53 (100) 0.72 0.086
Utility scores calculated by Malaysian utility tariff
All patients 104 (100) 0.75 53 (100) 0.82 0.014
Age at baseline (y)
o60 55 (52.9) 0.77 0.133 30 (56.6) 0.82 0.622
Z60 46 (44.2) 0.72 23 (43.4) 0.80
Missing 3 (2.9)
Sex
Male 91 (87.5) 0.76 0.036 50 (94.3) 0.81 0.814
Female 12 (11.5) 0.65 3 (5.7) 0.84
Missing 1 (1.0)
ACS diagnosis 0.71 0.80
NSTEMI/UA 45 (43.3) 0.78 0.045 23 (43.4) 0.83 0.410
STEMI 58 (55.8) 29 (54.7)
Missing 1 (0.9) 1 (1.9)
CV risk factors at baseline
o5 38 (36.5) 0.75 0.916 16 (30.2) 0.83 0.550
Z5 66 (63.5) 0.75 37 (69.8) 0.81
LVEF at baseline
r50% 55 (52.9) 0.75 0.874 21 (39.6) 0.81 0.775
450% 49 (47.1) 0.74 32 (60.4) 0.82
ACS, acute coronary syndrome; CV, cardiovascular; EQ-VAS, EQ-visual analogue scale; LVEF, left ventricular ejection fraction; NSTEMI, non–ST-
segment elevation myocardial infarction; STEMI, ST-segment elevation myocardial infarction; QOL, quality of life; UA, unstable angina; VAS,
visual analogue scale.
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component summary (PCS) and mental component summary
(MCS) scores from baseline to 6 months, with improvement in the
PCS score from 35.5 to 45.5 (P o 0.001) and the MCS score from
46.1 to 50.5 (P o 0.001), respectively [14]. Similarly, a study of
Portuguese patients with ACS reported signiﬁcantly higher PCS
and MCS scores from 55 at baseline to 63 (for PCS score) and 66
(for MCS score) after 12 to 20 months post-ACS. This is compared
to the population mean PCS and MCS scores of 72 and 61,
respectively [16]. A study of patients with ACS from Spain
reported a signiﬁcant reduction in PCS scores from 44.1 at base-
line to 42.8 (P ¼ 0.006) at follow-up. A major difference, however,
was that in the Spanish study, follow-up was performed much
earlier, at 3 months [18].
The advantages of using country-speciﬁc utility scores have
been reported by other authors as well as conﬁrmed through
previous studies [25,27–29,31]. Utility scores calculated from the
Malaysian utility tariff were higher than those calculated using
the UK tariff. The improvement in utility scores was found to be
statistically signiﬁcant (P o 0.05) when calculated using the
Malaysian tariff but not the UK tariff. The difference in mean
utility scores derived from different tariffs and the statistical
signiﬁcance of the improvement in QOL reconﬁrms the impor-
tance of applying health status data to the local population.
Previous studies have reported that the QOL of patients with
ACS and CV diseases during the initial admission and follow-up
was associated with demographic and clinical factors. These
include demographic factors such as age, sex, education, and
employment status [14–18] and clinical factors including type of
ACS diagnosis (STEMI or NSTEMI/UA), previous CV event, left
ventricular ejection fraction, and CV risk factors such as hyper-
tension, diabetes, and central obesity [14–16,18,33]. In the presentstudy, we found that utility scores of Malaysian patients with
ACS at baseline were associated with sex and diagnosis of STEMI
but not with age, the number of CV risk factors, or baseline left
ventricular ejection fraction. Furthermore, none of the demo-
graphic and clinical factors measured in the study was found to
be associated with utility scores at 12 months.
Our exploratory study has clear limitations. The relative lack of
signiﬁcant associations between demographic and clinical factors
and utility compared with previous studies is likely due to the
limited number of variables available for testing, which was reliant
on variables collected in the primary study. As mentioned, we had
used secondary data from a study designed to evaluate a cardiac
rehabilitation program. This limitation meant that it was not
possible to explore some of the other known factors that could
affect the QOL in patients with ACS such as physical activity,
central obesity, education, and smoking [14–16], which were not
available in the data set. Also, the number of subjects included was
relatively small compared with the sample sizes of other studies
[14,15,20]. Other limitations were that the small sample at baseline
was compounded by the loss of subjects during follow-up such that
only 53 subjects were available for analysis at 12 months post-ACS.
Finally, patients who had completed the cardiac rehabilitation
program may have gained a higher QOL at 12-month follow-up
compared with similar patients who were on standard care. This
may limit the generalizability of our QOL ﬁndings at 12 months to
other centers in Malaysia.Conclusions
Our study has shown that the QOL of patients with ACS in
Malaysia improved signiﬁcantly from the time of admission to
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were sex and type of ACS diagnosis. Utility scores varied depend-
ing on the tariff used in the calculation. Despite its limitations,
we think the study provides some insight into the QOL of patients
with ACS from a South East Asian country. The results also
remind us of the importance of applying local population utility
tariffs. Because CV disease is expected to increase in the coming
years due to socioeconomic growth, we hope that this study will
encourage more research and better understanding of the QOL of
patients with CV disease in this region. We foresee that local and
regional evidence would be important to improving the clinical
management and health outcomes of patients in each country.Acknowledgments
We thank the staff of the Cardiology Department and the Clinical
Research Centre at Sarawak General Hospital for their assistance.
We also thank the Director-General of Health in Malaysia for
permission to publish this article.
Funding source: The authors have no other ﬁnancial relation-
ships to disclose.
R E F E R E N C E S[1] Alwan A, Armstrong T, Bettcher D, et al., eds. for World Health
Organization. Global Status Report on Noncommunicable Disease 2010.
Geneva, Switzerland: World Health Organization, 2011.
[2] Centers for Disease Control and Prevention. QuickStats: number of
deaths from 10 leading causes—National Vital Statistics System, United
States, 2010. Morb Mortal Wkly Rep 2013;62:155.
[3] Ministry of Health Malaysia. Health Facts 2013. Health Informatics
Centre. Planning Division, Ministry of Health Malaysia, 2013: Available
from: http://vlib.moh.gov.my/cms/content.jsp?id=com.tms.cms.
document.Document_4336afb0-a02c4149-1b47cc20-40304b93.
[4] Chin SP, Jeyaindran S, Azhari R, et al. Acute coronary syndrome (ACS)
registry—leading the charge for National Cardiovascular Disease
(NCVD) Database. Med J Malaysia 2008;63(Suppl. C):29–36.
[5] World Health Organization. WHO-Malaysia: Country Cooperation
Strategy. Manila, Philippines: World Health Organization, 2010;2009–13.
[6] Overbaugh KJ. Acute coronary syndrome. Am J Nurs 2009;109:42–52;
quiz 53.
[7] Kumar A, Cannon CP. Acute coronary syndromes: diagnosis and
management, part I. Mayo Clin Proc 2009;84:917–38.
[8] Kumar PS, Clark M. Kumar and Clark’s Clinical Medicine (8th ed.).
Spain: Elsevier Ltd., 2012.
[9] Wan Ahmad WA, Sim KH. The Annual Report of the NCVD-ACS
Registry 2007 & 2008. Kuala Lumpur, Malaysia: National Cardiovascular
Disease Database, 2010.
[10] Brink E, Grankvist G, Karlson BW, et al. Health-related quality of life in
women and men one year after acute myocardial infarction. Qual Life
Res 2005;14:749–57.
[11] Bach JP, Riedel O, Pieper L, et al. Health-related quality of life in patients
with a history of myocardial infarction and stroke. Cerebrovasc Dis
2011;31:68–76.
[12] Izadnegahdar M, Norris C, Kaul P, et al. Basis for sex-dependent
outcomes in acute coronary syndrome. Can J Cardiol 2014;30:713–20.[13] Spertus JA, Jones P, McDonell M, et al. Health status predicts long-term
outcome in outpatients with coronary disease. Circulation
2002;106:43–9.
[14] Hawkes AL, Patrao TA, Ware R, et al. Predictors of physical and mental
health-related quality of life outcomes among myocardial infarction
patients. BMC Cardiovasc Dis 2013;13:69.
[15] De Smedt D, Clays E, Annemans L, et al. Health related quality of life in
coronary patients and its association with their cardiovascular risk
proﬁle: results from the EUROASPIRE III survey. Int J Cardiol
2013;168:898–903.
[16] Dias CC, Mateus P, Santos L, et al. Acute coronary syndrome and
predictors of quality of life. Revista Portuguesa de Cardiologia
2005;24:819–31.
[17] Brink E. Considering both health-promoting and illness-related factors
in assessment of health-related quality of life after myocardial
infarction. Open J Nurs 2012;6:90–4.
[18] Failde E II, Soto MM. Changes in health related quality of life 3
months after an acute coronary syndrome. BMC Public Health
2006;6:18.
[19] Grothusen C, Attmann T, Friedrich C, et al. Predictors for long-term
outcome and quality of life of patients after cardiac surgery with
prolonged intensive care unit stay. Interv Med Appl Sci 2013;5:
3–9.
[20] Pavlides G, Drossinos V, Dafni C, et al. Current management and
quality of life of patients with acute coronary syndrome undergoing
percutaneous coronary intervention in Greece: 12-month results from
antiplatelet therapy observational study II (APTOR II). Hellenic J Cardiol
2013;54:255–63.
[21] Rumsfeld JS, Magid DJ, Plomondon ME, et al. History of depression,
angina, and quality of life after acute coronary syndromes. Am Heart J
2003;145:493–9.
[22] Dyer MT, Goldsmith KA, Sharples LS, et al. A review of health utilities
using the EQ-5D in studies of cardiovascular disease. Health Qual Life
Outcomes 2010;8:13.
[23] Robin R, Oemar M, Oppe M. EQ-5D-3 L User Guide: Basic Information on
How to Use the EQ-5D-3 L Instrument. The Netherlands: EuroQol
Group, 2011.
[24] Weinstein MC, Torrance G, McGuire A. QALYs: the basics. Value Health
2009;12(Suppl. 1):S5–9.
[25] Lee YK, Nam HS, Chuang LH, et al. South Korean time trade-off values
for EQ-5D health states: modeling with observed values for 101 health
states. Value Health 2009;12:1187–93.
[26] Dolan P. Modeling valuations for EuroQol health states. Med Care
1997;35:1095–108.
[27] Tsuchiya A, Ikeda S, Ikegami N, et al. Estimating an EQ-5D population
value set: the case of Japan. Health Econ 2002;11:341–53.
[28] Szende A, Oppe M, Devlin N. EQ-5D Value Sets: Inventory, Comparative
Review and User Guide. EuroQol Group Monographs. Dordrecht:
Springer, 2007.
[29] Shaw JW, Johnson JA, Coons SJ. US valuation of the EQ-5D health states:
development and testing of the D1 valuation model. Med Care
2005;43:203–20.
[30] Yusof FA, Goh A, Azmi S. Estimating an EQ-5D value set for Malaysia
using time trade-off and visual analogue scale methods. Value Health
2012;1(Suppl.)5):S85–90.
[31] Jelsma J, Hansen K, De Weerdt W, et al. How do Zimbabweans value
health states? Pop Health Metrics 2003;1:11.
[32] Azmi S, Anchah L, Goh A, et al. Comparing quality of life in Malaysian
post acute coronary syndrome population using EQ-5D utility tariffs
from different countries. Presented at: ISPOR 17th Annual International
Meeting. Washington, DC, June 2-6, 2012.
[33] Lewis EF, Li Y, Pfeffer MA, et al. Impact of cardiovascular events on
change in quality of life and utilities in patients after myocardial
infarction: a VALIANT study (Valsartan In Acute Myocardial Infarction).
JACC Heart Failure 2014;2:159–65.
